Pyrosequencing

Pixelgen Technologies Appoints Mostafa Ronaghi to Scientific Advisory Board

Retrieved on: 
Tuesday, April 30, 2024
Stanford University, Membrane, Karolinska Institute, Genomics, Mostafa Ronaghi, Pyrosequencing, Pixelation, Clear Labs, Proteome, Imperial College London, Culture, GRAIL, Drug development, Management

STOCKHOLM, April 30, 2024 /PRNewswire/ -- Pixelgen Technologies announced today the appointment of Mostafa Ronaghi, Ph.D., to its Scientific Advisory Board.

Key Points: 
  • STOCKHOLM, April 30, 2024 /PRNewswire/ -- Pixelgen Technologies announced today the appointment of Mostafa Ronaghi, Ph.D., to its Scientific Advisory Board.
  • "Mostafa is a recognized life sciences visionary leader, with deep expertise in genomics and a tested entrepreneurial spirit," said Pixelgen CEO Simon Fredriksson.
  • "These attributes align well with Pixelgen's mission and culture, and we are honored to have him on our board.
  • "I'm thrilled to join Pixelgen's Scientific Advisory Board and look forward to working with the company's impressive team to continue developing Molecular Pixelation," Ronaghi said.

Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors

Retrieved on: 
Thursday, April 11, 2024
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, Doctor of Philosophy, Genomics, Mostafa Ronaghi, Pyrosequencing, Trauma, Clear Labs, NGS, Senior, Translation, GRAIL, SMMT, Organization, Royal institute, Management

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Mostafa Ronaghi, PhD, has been appointed to its Board of Directors, effective immediately.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Mostafa Ronaghi, PhD, has been appointed to its Board of Directors, effective immediately.
  • “We are excited to add Dr. Ronaghi to complement our excellent group of current board members,” stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit.
  • As we intend to maximize the potential of ivonescimab, we are excited to add the acumen and expertise that Mostafa can bring to our impressive executive team.”
    Dr. Ronaghi is the Co-Founder and Executive Board Member of Cellanome.
  • “I am very pleased at the opportunity to join Summit’s Board of Directors,” said Dr. Ronaghi.

Gyros Protein Technologies and Biotage partner to advance peptide purification efficiency with new automated solution

Retrieved on: 
Thursday, December 7, 2023
Other Health, Radiology, Research, Pharmaceutical, Optical, Oncology, Mental Health, Medical Devices, Infectious Diseases, Hospitals, Fitness & Nutrition, Dental, Clinical Trials, Cardiology, Stem Cells, Science, Biotechnology, Practice Management, Alternative Medicine, Nursing, AIDS, Managed Care, Medical Supplies, Health, FDA, Diabetes, Peptide, HPLC, Multimedia, Pyrosequencing, Workflow, Automation, Drug discovery, Partnership, Fine chemical

Gyros Protein Technologies AB, a leading provider of peptide synthesizers and reagents and a pioneer in automated nanoliter-scale immunoassays, and Biotage, a global life sciences company, providing high-quality purification and sample preparation solutions, today announced a partnership to offer Biotage® PeptiPEC, based on Gyros’ PurePep® EasyClean (PEC™) catch and release technology, on Biotage® Extrahera™ automated sample preparation system.

Key Points: 
  • Gyros Protein Technologies AB, a leading provider of peptide synthesizers and reagents and a pioneer in automated nanoliter-scale immunoassays, and Biotage, a global life sciences company, providing high-quality purification and sample preparation solutions, today announced a partnership to offer Biotage® PeptiPEC, based on Gyros’ PurePep® EasyClean (PEC™) catch and release technology, on Biotage® Extrahera™ automated sample preparation system.
  • The development of an automated plate-based peptide purification workflow provides a fast and environmentally sustainable solution for high-throughput peptide purification.
  • Parallel peptide synthesis generates crude peptide samples at a rate that surpasses the capacity of HPLC, the most common method of peptide purification, which is particularly evident when purifying more than 24 peptides simultaneously.
  • Tomas Blomquist, CEO, Biotage, said: “We’re excited to be partnering with Gyros Protein Technologies to bring a plate-based automated solution for parallel high-throughput peptide purification to market, removing bottlenecks for peptide scientists, and providing a complete workflow solution from synthesis to evaporation.

Global Chromatography Market Expected to Reach USD 10.5 Billion in 2023 with 5.5% CAGR Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 6, 2023
Other Science, Science, Bio-Rad Laboratories, Partnership, Food, Pyrosequencing, Waters, Waters Corporation, Biotechnology, COVID-19, Chromatography, Thermo Fisher Scientific, Type, USD, Compound annual growth rate, PerkinElmer, Name, COVID-19 vaccine, Acquisition, Patent, Laboratory, Sartorius, Agilent Technologies, Medicine, Drug discovery, Growth, Applied science, Valmet, Pall Corporation, HPLC, Automation, Fine chemical, Retail, Vaccine

The global landscape of chromatography is set for a dynamic transformation, with an estimated market value of USD 10.5 billion in 2023.

Key Points: 
  • The global landscape of chromatography is set for a dynamic transformation, with an estimated market value of USD 10.5 billion in 2023.
  • Encompassing the chromatography instrumentation market, including liquid chromatography systems, gas chromatography systems, gel permeation chromatography, and more, along with the chromatography consumables market, this industry is poised to achieve a Compound Annual Growth Rate (CAGR) of 5.5% during the forecast period.
  • These include liquid chromatography systems, gas chromatography systems, gel permeation chromatography, supercritical fluid chromatography, and a range of chromatography consumables like chromatography resins and columns.
  • Market Analysis: The global chromatography market is estimated to reach USD 10.5 billion in 2023, with a projected CAGR of 5.5%.

Plasmid DNA Manufacturing Global Market Report 2022: Surging Number of Patients Choosing Gene Therapy as Their Treatment to Fuel Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 23, 2022
Health, Genetics, Growth, Region, USD, Pyrosequencing, Government, Leber congenital amaurosis, Plasmid, DNA, RPE65, Patient, Vaccine, Disease

The "Plasmid DNA Manufacturing Market by Grade, Development Phase, Application, Disease, and by Region - Global Forecast to 2022-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Plasmid DNA Manufacturing Market by Grade, Development Phase, Application, Disease, and by Region - Global Forecast to 2022-2033" report has been added to ResearchAndMarkets.com's offering.
  • Rising demand for plasmid (pDNA) DNA, growing public understanding of cell & gene therapy, surging number of patients choose gene therapy as their treatment of choice are factors contributing to the market growth.
  • Furthermore, increasing number of partnerships or collaborations between the many entities participating in this sector emphasises the growing interest in the manufacturing of plasmid DNA.
  • Surging number of patients choosing gene therapy as their treatment is predicted to fuel the market growth.

Opentrons Robotics Launches New Workstations to Support Genomics and Proteomics Applications

Retrieved on: 
Thursday, March 10, 2022
Technology, Research, Genetics, Other Technology, Biotechnology, Health, Pharmaceutical, Other Science, Science, Industry, Genomics, NGS, RNA transfection, PCR, COVID-19 testing, Automation, Research, Workflow, Molecular biology, Magnetism, Pyrosequencing, Robotics, PRL, Solution, COVID-19, Drug discovery, Opentrons, Proteomics, Fine chemical, Vaccine, Opentrons Labworks, Inc., Opentrons Robotics, OPENTRONS LABWORKS, INC., OPENTRONS ROBOTICS

The expansion of our OT-2 portfolio will bring the benefits of radically simple, accessible automation to new customers, said David Kim, general manager of Opentrons Robotics.

Key Points: 
  • The expansion of our OT-2 portfolio will bring the benefits of radically simple, accessible automation to new customers, said David Kim, general manager of Opentrons Robotics.
  • Opentrons new workstations will bring all these benefits to scientists working across genomics and proteomics applications.
  • Through our business unit, Opentrons Robotics, thousands of institutions are automating R&D operations with flexible, easy-to-use lab robots.
  • Opentrons Robotics, a business unit of Opentrons Labworks, Inc., is the industry leader in flexible, user-friendly automation for life science R&D labs.

Biotage Awarded Gold Sustainability Medal by EcoVadis

Retrieved on: 
Thursday, February 24, 2022
Health, Food safety, BIOT, Sustainable procurement, Water, Gold, Group, Ethics, Organization, Environment, Heart, Labour, Nasdaq Stockholm, Science, Gold medal, Drug discovery, Human, Capital, Solution, CEO, Human rights, Fine chemical, Pyrosequencing

As part of HumanKind Unlimited comes a commitment to sustainability at every level within Biotage and within every customer relationship.

Key Points: 
  • As part of HumanKind Unlimited comes a commitment to sustainability at every level within Biotage and within every customer relationship.
  • EcoVadis, a leading producer of supplier sustainability ratings, recently recognised this commitment by awarding Biotage the Gold Medal in sustainability, after a thorough audit of Biotage's performance with respect to the Environment, Labor & Human Rights, Ethics and Sustainable Procurement.
  • The gold Medal rating places Biotage in the top 5% of global suppliers across all industries.
  • Biotage is contributing to sustainable science with the goal to make the world healthier, greener and cleaner HumanKind Unlimited.

Biotage AB (publ) Year-end report January - December 2021

Retrieved on: 
Friday, February 11, 2022
APAC, Time, Analytical chemistry, Record, Board of directors, Organic chemistry, CFO, Carbon, RNA, Solution, Vaccine, Annual, Pyrosequencing, PCR, International, Gold, SEK, Board, Policy, Acquisition, Growth, Investment, DNA, EBITA, COVID-19, EBIT, Director, Aquaculture, Fossil fuel, Security (finance), Holding company, Sales, Fine chemical, EMEA, Biomolecule

Net sales amounted to SEK 1,232 (1,092) million, an increase of 12.7 percent and an organic* growth of 17.5 percent.

Key Points: 
  • Net sales amounted to SEK 1,232 (1,092) million, an increase of 12.7 percent and an organic* growth of 17.5 percent.
  • According to the dividend policy Biotage shall distribute at least 50 percent of the net profit.
  • Biotage has managed to deal with the global challenges in the supply chain and ended 2021 with another sales record in the fourth quarter.
  • I am extremely proud of the steps Biotage has taken on its profitable growth journey in 2021.

Biotage moves to the large cap segment

Retrieved on: 
Monday, January 3, 2022
Pyrosequencing, Nasdaq Stockholm, CEO, Group, Science, Organization, Food safety, Capital, Water, BIOT, Drug discovery, Industrial design, Food industry, Fine chemical

UPPSALA, Sweden, Jan. 3, 2022 /PRNewswire/ -- As of today January 3, 2022, Biotage is included in Nasdaq Stockholm's Large Cap segment.

Key Points: 
  • UPPSALA, Sweden, Jan. 3, 2022 /PRNewswire/ -- As of today January 3, 2022, Biotage is included in Nasdaq Stockholm's Large Cap segment.
  • The Large Cap segment includes companies with a market capitalization of more than EUR 1 billion.
  • "Biotage continues to create value for our customers, owners and other interested parties and we consider the move to the Large Cap segment as yet another quality label and confirmation of that.
  • Biotage's share (BIOT) is listed in the Large Cap segment on the NASDAQ Stockholm.

New composition of Biotage Nomination Committee

Retrieved on: 
Monday, December 13, 2021
Ownership, Board, Annual general meeting, Water, Letter, Committee, Capital, Nasdaq Stockholm, Food safety, Person, Annual, Director, Nomination, Science, Group, Organization, BIOT, Drug discovery, Pyrosequencing

The members of the Nominations Committee are:

Key Points: 
  • The members of the Nominations Committee are:
    Joachim Spetz, appointed by Swedbank Robur Fonder, chairman
    Shareholders wishing to submit a proposal to the Nomination Committee may do so by sending e-mail to the Chairman of the Board of Directors of Biotage AB at: [email protected] .
  • Proposals should, in order to be timely assessed by the Nomination Committee, be submitted no later than seven weeks in advance of the meeting.
  • The Annual General Meeting 2022 in Biotage will be held on Thursday, April 28, 2022 at 4:00pm CET in Uppsala.
  • Biotage is contributing to sustainable science with the goal to make the world healthier, greener and cleaner HumanKind Unlimited.